-
Mashup Score: 1Hematologists Dive into the Current Treatment Landscape - 5 month(s) ago
Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Hematologists Dive into the Current Treatment Landscape - 5 month(s) ago
Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Hematologists Dive into the Current Treatment Landscape @MCWCancerCenter @Froedert @OncLiveSOSS #OncLiveIPC https://t.co/iIVLqa9xnJ
-
-
Mashup Score: 1Hematologists Dive into the Current Treatment Landscape - 5 month(s) ago
Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Hematologists Dive into the Current Treatment Landscape @MCWCancerCenter @Froedert @OncLiveSOSS #OncLiveIPC https://t.co/iIVLqa9xnJ
-
-
Mashup Score: 1Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management - 6 month(s) ago
Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management @AlanBryce9 @sartor_oliver @MayoCancerCare @MayoClinicSOM #OncLiveIPC #blcsm #pcsm https://t.co/Qx4amUsNuL
-
-
Mashup Score: 1
Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormome receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer @KariWisinski_MD @malindatwestmd @LubnaChaudhary1 @meburkard @marina_sharifi @UWCarbone @medicalcollege #OncLiveIPC #bcsm https://t.co/hPMpqGfyPE
-
-
Mashup Score: 0Events | Clinical Oncology Events & Registration | OncLive - 7 month(s) ago
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the past 3 years, we've produced and hosted over 700 hours of non-CE educational events. Find your next event here 👉 https://t.co/bwcZBmOGSf #oncology #education #OncLiveIPC #OncLiveSOSS #doyouknowonclive https://t.co/8GYAR9x4lR
-
-
Mashup Score: 0Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer - 7 month(s) ago
Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma. @UCSFCancer #OncLiveIPC #oncology https://t.co/IruS6ihKHK
-
-
Mashup Score: 0Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes - 7 month(s) ago
Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer. @DrJairamK @killthecancer @unmc @uiowa #OncLiveIPC #bcsm https://t.co/mtVyK30V0o
-
-
Mashup Score: 0Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies - 7 month(s) ago
Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Amy W. Zhou, MD, highlights the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis. @mpndoc @KSanfillipoMD @SanaSaifUrRehm @WUSTLmed @UChicago #OncLiveIPC #oncology https://t.co/LA5YrFkFfI https://t.co/V2AfGX1rY4
-
-
Mashup Score: 0Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer - 7 month(s) ago
Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer @UCSFCancer #OncLiveIPC #oncology https://t.co/IruS6ihcSc
-
Hematologists Dive into the Current Treatment Landscape @MCWCancerCenter @Froedert @OncLiveSOSS #OncLiveIPC https://t.co/iIVLqa9xnJ